Biopharma & Life Sciences
Ardelyx Executive Compensation (FY25)
ARDX · Executive and director compensation, fiscal 2025 only
Data as of September 7, 2026Latest filing (8-K): June 17, 2026
203 figures on this page: 197 cited to the filing that reported them, 6 calculated from figures it prints. See the citations
Michael Raab was paid $7,796,171 in total compensation as President, Chief Executive Officer and Director for fiscal 2025, and the company reported a chief executive pay ratio of 25:1 for fiscal 2025, against median employee compensation of $311,004. The say-on-pay proposal drew 93.6% of votes cast for or against in favor at the meeting held June 16, 2026 for fiscal 2025. Separately, the disclosed peer group includes ADMA Biologics, Inc., Amicus Therapeutics, Inc., Arcutis Biotherapeutics, Inc., BioCryst Pharmaceuticals, Inc. and Catalyst Pharmaceuticals, Inc., among others; the company reported 6 named executive officers for fiscal 2025.
Frequently asked questions
Answers drawn from the data on this page.
Who is Ardelyx's chief executive and what were they paid?
Michael Raab was paid $7,796,171 in total compensation as President, Chief Executive Officer and Director for fiscal 2025.
What was Ardelyx's say-on-pay result?
The say-on-pay proposal drew 93.6% of votes cast for or against in favor at the meeting held June 16, 2026 for fiscal 2025.
Which companies are in Ardelyx's peer group?
The disclosed peer group includes ADMA Biologics, Inc., Amicus Therapeutics, Inc., Arcutis Biotherapeutics, Inc., BioCryst Pharmaceuticals, Inc. and Catalyst Pharmaceuticals, Inc., among others.
What is Ardelyx's chief executive pay ratio?
The company reported a chief executive pay ratio of 25:1 for fiscal 2025, against median employee compensation of $311,004.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Michael Raab President, Chief Executive Officer and Director | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Edward Conner Former Chief Medical Officer Departed during or after this year | ◇ | — | ◇ | ◇ | — | — | — | ◇ |
Justin Renz Former Chief Financial and Operations Officer Departed during or after this year | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Susan Hohenleitner Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | — | ◇ |
John Bishop Chief Technical and Quality Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Elizabeth Grammer Former Chief Legal and Administrative Officer Departed during or after this year | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Edward Conner | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Edward Conner | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Elizabeth Grammer | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Elizabeth Grammer | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| John Bishop | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| John Bishop | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Justin Renz | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Justin Renz | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Justin Renz | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Justin Renz | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Justin Renz | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Justin Renz | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Justin Renz | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Justin Renz | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Justin Renz | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Michael Raab | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Michael Raab | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Susan Hohenleitner | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Susan Hohenleitner | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Michael Raab | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/16/2034 | |
| Option | ◇ | — | ◇ | 1/5/2033 | |
| Option | ◇ | — | ◇ | 2/25/2035 | |
| Option | ◇ | — | ◇ | 1/6/2032 | |
| Susan Hohenleitner | Option | ◇ | — | ◇ | 10/13/2035 |
| RSU | ◇ | ◇ | — | — | |
| Elizabeth Grammer | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/5/2033 | |
| Option | ◇ | — | ◇ | 1/6/2032 | |
| Option | ◇ | — | ◇ | 2/25/2035 | |
| Option | ◇ | — | ◇ | 1/16/2034 | |
| RSU | ◇ | ◇ | — | — | |
| John Bishop | Option | ◇ | — | ◇ | 7/14/2035 |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Merdad Parsey | ◇ | ◇ | ◇ | — | — | — | ◇ |
David Mott Board chair | ◇ | ◇ | ◇ | — | — | — | ◇ |
Richard Rodgers | ◇ | ◇ | ◇ | — | — | — | ◇ |
William Bertrand, Jr | ◇ | ◇ | ◇ | — | — | — | ◇ |
Muna Bhanji | ◇ | ◇ | ◇ | — | — | — | ◇ |
Robert Bazemore | ◇ | ◇ | ◇ | — | — | — | ◇ |
Onaiza Cadoret-Manier | ◇ | ◇ | ◇ | — | — | — | ◇ |
Michael Raab served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Compensation committee chair | ◇ |
| Nominating and governance chair | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- ADMA Biologics, Inc. ADMA
- Amicus Therapeutics, Inc. FOLD
- Arcutis Biotherapeutics, Inc. ARQT
- BioCryst Pharmaceuticals, Inc. BCRX
- Catalyst Pharmaceuticals, Inc. CPRX
- Collegium Pharmaceutical, Inc. COLL
- Dynavax Technologies Corporation DVAX
- Evolus, Inc. EOLS
- Innoviva, Inc. INVA
- Ironwood Pharmaceuticals, Inc. IRWD
- MannKind Corporation MNKD
- Mirum Pharmaceuticals, Inc. MIRM
- Ocular Therapeutix, Inc. OCUL
- Rhythm Pharmaceuticals, Inc. RYTM
- Tarsus Pharmaceuticals, Inc. TARS
- TG Therapeutics, Inc. TGTX
- Travere Therapeutics, Inc. TVTX
- Vericel Corporation VCEL
- Xencor, Inc. XNCR
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 16, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 18, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 14, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | June 15, 2023 | = | ◇ | ◇ | ◇ |
| 2020 | June 16, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | June 9, 2020 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Ardelyx disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Ardelyx sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
203 figures on this page: 197 cited to the filing that reported them, 6 calculated from figures it prints.
197 cited to the filing
6 calculated from the filing
Documents cited
- 0001437402-26-000029Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001140361-26-0178002025 Director Compensation Table · 2025 Summary Compensation Table · CEO Pay Ratio · Grants of Plan-Based Awards · and 2 more sections
- 0001628280-25-032172Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001628280-24-028413Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001628280-23-022681Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001628280-21-012532Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001558370-20-007400
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Ardelyx executive compensation, FY2025.” https://intel.velarion.ai/comp/ARDX (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Ardelyx and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Ardelyx discloses
The companies named in ARDX's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}